These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 39104592)

  • 1. Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.
    Shaikh MS; Faiyazuddin M; Khan MS; Pathan SK; Syed IJ; Gholap AD; Akhtar MS; Sah R; Mehta R; Sah S; Bonilla-Aldana DK; Luna C; Rodriguez-Morales AJ
    Front Microbiol; 2024; 15():1413250. PubMed ID: 39104592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A measles virus-based vaccine induces robust chikungunya virus-specific CD4
    Schmitz KS; Comvalius AD; Nieuwkoop NJ; Geers D; Weiskopf D; Ramsauer K; Sette A; Tschismarov R; de Vries RD; de Swart RL
    Vaccine; 2023 Oct; 41(43):6495-6504. PubMed ID: 37726181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Progress in Vaccine Development Against Chikungunya Virus.
    Gao S; Song S; Zhang L
    Front Microbiol; 2019; 10():2881. PubMed ID: 31921059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
    Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
    Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
    Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.
    Muthumani K; Lankaraman KM; Laddy DJ; Sundaram SG; Chung CW; Sako E; Wu L; Khan A; Sardesai N; Kim JJ; Vijayachari P; Weiner DB
    Vaccine; 2008 Sep; 26(40):5128-34. PubMed ID: 18471943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
    Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
    J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus.
    Cao L; Wang W; Sun W; Zhang J; Han J; Xie C; Ha Z; Xie Y; Zhang H; Jin N; Lu H
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.
    Ge N; Sun J; Liu Z; Shu J; Yan H; Kou Z; Wei Y; Jin X
    Virol Sin; 2022 Apr; 37(2):266-276. PubMed ID: 35527225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.
    Weber WC; Streblow DN; Coffey LL
    BioDrugs; 2024 Nov; 38(6):727-742. PubMed ID: 39292392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chikungunya Virus: Priority Pathogen or Passing Trend?
    Montalvo Zurbia-Flores G; Reyes-Sandoval A; Kim YC
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
    Yang S; Fink D; Hulse A; Pratt RD
    Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
    Metz SW; Pijlman GP
    Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.